Login to Your Account

Orphan Drugs Market Becoming Major Business for Industry

By Peter Winter

Monday, April 29, 2013

A quick scan through the drug pipelines of many biotechnology and pharmaceutical companies will reveal a significant number of drugs under development that have received "orphan drug status." Yet, it wasn't all that long ago that orphan drugs were considered too small to devote valuable R&D resources. As a consequence they did not feature prominently on the product development radar screens of either pharma or biotech companies.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription